Astellas Pharma Inc. (TYO:4503)
Japan
· Delayed Price · Currency is JPY 1,396.00
-12.00 (-0.85%)
May 9, 2025, 3:30 PM JST
Astellas Pharma Revenue
In the fiscal year ending March 31, 2025, Astellas Pharma had annual revenue of 1.91T JPY with 19.25% growth. Astellas Pharma had revenue of 459.29B in the quarter ending March 31, 2025, with 10.78% growth.
Revenue
1,912.32B
Revenue Growth
+19.25%
P/S Ratio
1.32
Revenue / Employee
129.61M
Employees
14,754
Market Cap
2,520.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,912.32B | 308.65B | 19.25% |
| Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
| Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
| Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
| Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,579.02B |
| HOYA Corporation | 869.37B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,393.18B |
| Olympus | 993.33B |
| Shionogi & | 456.87B |
Astellas Pharma News
- 7 days ago - Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses - PRNewsWire
- 12 days ago - Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Astellas Pharma reports FY results - Seeking Alpha
- 22 days ago - Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation - Business Upturn
- 23 days ago - Zydus down 5%, Lupin down nearly 4% as US court orders withdrawal of Myrbetriq drug - Business Upturn
- 6 weeks ago - Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting - GlobeNewsWire
- 7 weeks ago - Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward - Seeking Alpha
- 2 months ago - Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing - PRNewsWire